scPharmaceuticals Inc.: insider trades · United States · SEC (Form 4)

About scPharmaceuticals Inc.

scPharmaceuticals Inc. is a United States biopharmaceutical company listed on the NASDAQ market in the United States, with headquarters in Burlington, Massachusetts. The company was formed in February 2013 in Delaware and has built its strategy around a highly specialized niche: converting therapies that are traditionally given intravenously into simpler, patient-friendly solutions that can be administered at home or in outpatient settings. Its business model is centered on drug-device combination products, with a clear focus on cardiorenal care. The company’s core commercial asset is FUROSCIX, a subcutaneous formulation of furosemide delivered through a wearable on-body infusor. FUROSCIX is designed to treat congestion due to fluid overload in adults with chronic heart failure, and in March 2025 the FDA approved an expanded indication for edema in patients with chronic kidney disease. That label expansion materially broadens the product’s commercial opportunity and supports the investment case around a large clinical need: reducing avoidable hospital visits and simplifying care delivery for patients with fluid-overload conditions. From a competitive standpoint, scPharmaceuticals differentiates itself as an early mover in the at-home subcutaneous delivery of loop diuretics. The company is addressing a market tied to heart failure, volume overload and broader cardiorenal management, where the value proposition is both clinical and economic. Its competitive edge comes from the convenience of the delivery system, the product’s technology differentiation, and its ability to fit into post-acute and chronic care pathways where payers and providers increasingly seek lower-cost alternatives to inpatient infusion. Over the past several quarters, management has focused on commercial execution for FUROSCIX and on regulatory expansion of the franchise. Recent milestones include FDA acceptance and subsequent approval of the CKD supplemental NDA, along with continued revenue growth in 2024 and early 2025. In 2025, the company also reported quarterly financial results and highlighted launch preparations for the new indication. For French-speaking investors, scPharmaceuticals represents a U.S. healthcare small cap with a concentrated risk profile, reliant on the commercial success of a single lead product and on disciplined execution across regulatory, medical and commercial fronts in the United States.